IFI Members in the News
April 20, 2015
The immunotherapy drug known as PD-1 bested the stadard of care in advanced melanoma, researchers reported at the 2015 AACR Annual Meeting. Patients on pembrolizumab (PD-1) had better overall survival and progression free survival rates compared to patients on ipilimumab. "Again and again, new immune therapies are producing meaningful outcomes for our patients, "Robert Vonderheide, MD, DPhil, a professor of Medicine in the division of Hematology/Oncology at the Abramson Cancer Center told Forbes. " The breakthrough drug approved four years ago is now seemingly surpassed, with less toxicity."
April 20, 2015
Two immunotherapy drugs taken together for melanoma - ipilimumab and nivolumab - held the cancer at bat longet than ipilimumab alone, reserachers reported at the 2015 AACR Annual Meeting, reports the Associated Press. "It's reassuring and adds really important information about (the effects) of giving these two agents together," said Lynn Schuchter, MD, chief of Hematology/Oncology at the Abramson Cancer Center. Schuchter doesn't think patients needs to take such potent drugs together. More research, expected in the near future may clairify what is best, she said.
April 17, 2015
The American Association for Cancer Research annual meeting, expected to draw over 18,000 cancer researchers and physicians from around the world, begins this weekend in Philadelphia, reports the Philadelphia Inquirer. "It's a stunning meeting," said Robert H. Vonderheide, MD, DPhil, professor of Medicine in the division of Hematology/Oncology in the Abramson Cancer Center. "It instigates collaborations. It helps fund our work. It provides a voice for the work we do."
April 15, 2015
In continuing coverage, a segment from Nightline features Penn patients Michele and Matt Crane, and their kidney transplant surgeons, Peter Abt, MD, associate professor of Surgery, and Ali Naji, MD, PHD, surgical director of the Kidney and Pancreas Transplant Program. Last month, Matt and Michele participated in what is now the longest multi-hospital kidney transplant chain in U.S. history. Over the course of three months, 68 lives were changed when 34 kidneys were swapped between 26 different hospitals across the nation. "It is a huge operation, but it's driven by the hears and minds of people who want to do it. If there was no love in this, it wouldn't happen," said Naji.
April 14, 2015
In continuing coverage, a post from Dr. Francis Collins to his NIH Director's Blog reports on the recent Penn-led study published in JAMA which found that among women with mutations in BRCA1/2 genes, the answer to whether a particular individual will develop breast cancer, ovarian cancer, both types of cancer, or neither cancer appears to vary considerably depending upon the precise type of mutation inherited and the locations of these mutations in the DNA sequences of the genes. The post states that the new work by Timothy Rebbeck, PhD, associate professor of Population Science in the Abramson Cancer Center, Katherine L. Nathanson, MD, associate professor of Medicine and director of Genetics in the Basser Center for BRCA, and collegues represents a significant step toward more precise and individualized risk calculations.
April 14, 2015
A sudy led by Timothy Rebbeck and Katherine Nathanson of Medicine found that the risk of breast and ovarian cancer differs depending on a BRCA1 or BRCA2 mutation.
April 13, 2015
In a Medpage Today "10 Questions" article, Mariell Jessup, MD, associate chief of clinical affairs in the division of Cardiology and medical director of the Penn Medicine Heart and Vascular Center, shares her thoughts on a variety of topics - from treatment barriers to advice to other physicians.
April 9, 2015
A Philadelphia In uirer story examines progress in various types of immunotherapiesfor the treatment of cancer. "We have tried to learn from the early days of gene therapy and avoid the hype," said Carl June, MD, a profesor of Pathology and Laboratory Medicine and director of Translational Research in Abramson Cancer Center. "What I say in general is, it's the early days, so we don't know everything. We need to have decades of observations. But so far, the toxicity [of immunotherapy] has been less" than conventional oncology weapons.
Penn Medicine, Abramson Cancer Center Team Continues Progress in Investigational Gene Therapy for Blood Cancers
April 8, 2015
The University of Pennsylvania research team behind pioneering studies of an investigational personalized cellular therapy for blood cancers has announced that the United States Patent and Trademark Office has issued several new patents on technologies related to this therapy, known as CTL019. "We are proud to have successifully treated patients with advanced leukemia and lymphoma and to continue refining this therapy and developing new CARs to treat other types of cancers." said Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in Penn's Perelman School of Medicine, and director of Translational Reserach in the Abramson Cancer Center.
April 8, 2015
In continuing coverage, WHYY radio reported on a new study from Penn researchers which shows that the type and location of BRCA mutation helps determine whether women are more likely to develop breast or ovarian cancer. "It doesn't mean you won't get breast cancer or you won't get ovarian cancer," said senior author Katherine L. Nathanson, MD, associate professor of Medicine and director of Genetics in the Basser Center for BRCA and chirf oncogenomics physician in the Abramson Cancer Center. "There's just some relative differences depending on where the mutation is." Lead author Timothy Rebbect, PhD, associate professor of Population Sciences in the Abramson Cancer Center, was quoted in outlets across the antion, influding Reuters Health, HealthDay, and NBC News.
April 7, 2015
HIV-positive kidney-transplant patients had better outcomes when compared to patients with hepatits C, accourding to a study by Deirdre Sawinski of Medicine.
April 1, 2015
Valder Arruda and Julie Crudele of CHOP and the Perelman School of Medicine have produced a mutant protein with high blood-clotting power to treat hemophilia in dogs.
March 30, 2015
A three-part PBS film "Cancer: The Emperor of All Maladies," presented by Ken Burns, will feature the story of the first pediatric patient to receive Penn's modified T cell therapy for leukemia. Carl June, MD, a professor in the department of Pathology and Laboratoy Medicine and director of Translational Research in Penn's Abramson Cancer Center, and Stephan Grupp, MD, PhD, a professor of Pediatrics and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia, are featured in the film, along with Emily Whitehead and her parents, Tom and Kari Whitehead. Multiple news outlets covered Penn's role in the fil, which ends with an examination of promising Immunotherapies. The film, which is based on the Pullitzer Prize-winning book, "The Emperor of All Maladies: A Biography of Cancer." will air on PBS affiliates across the United States from 9-11 pm for three consecutive evenings, beginning tonight. Emily Whitehead's story appears in the film's final night, April 1.
March 27, 2015
In continuing coverage of Angelia Jolie Pits's decision to publicly discuss preventive measures taken to reduce the risk of cancers associated with BRCA mutations, Narure reports on the state of genetic testing. Thousands of possible mutations in BRCA1 and BRCA2 genes elevate a woman's risk of deloping cancer, but it is impossible to say whether many of these mutaions predispose someone to cancer, because researchers have not seen them enough to know their effects with statistical certainty. "As more and more people are tested, and you identify more and more people with a certain variant, it can go from being a variant of unknown significance to a benighn variant, it can gr from being a variant of unknown significance to a benign variant," syas Katherine Nathanson, MD associate professor of Medicine and director of Genetics at the Basser Research Center for BRCA in the Abramson Cancer Center.
March 24, 2015
The Immunology Graduate Group is #6 again this year in the U.S. News & World Report rankings of Best Graduate Schools. According to U.S. News, Penn is one of "the best science schools for immunology/infectious disease." See the U.S. News & World Report website for a list of programs.
March 24, 2015
Researchers like Carl June of the Perelman School of Medicine are investigating a potential cancer cure by using manipulated virus cells to achieve remision.
March 23, 2015
Carl June of Medicine, an expert on cancer and HIV, has been awarded the 2015 Paul Ehrilich and Ludwig Darmstaedter Prize for his work in immunotherapy.
March 18, 2015
A PBS NewsHour segment traces the story of Penn Medicine's work developing and testing an experimental personalized cellular therapy for cancer, highlighting both promising results in clinical trials for patients with blood cancers and the potential of the therapy in a newly launched trial for patients with brain cancer. Members of the research team including Carl June, MD, David Porter, MD Marcela Maus, MD, PhD, and Donald O'Rourke, MD are quoted in the story, along with a leukemia patient who is in remission after receiving the therapy last year.
March 17, 2015
A study led by Medicine's Andy Minn suggests that radiation along with two immunotherapies may be more effective in helping shrink metastatic melanoma tumors.
March 2, 2015
Two of the four groups of human AIDS viruses originated in western lowland African gorillas, according to research by Beatrice Hahn of the Perelman School of Medicine.
Radiation Plus Immunotherapy Combo Revs up Immune System to Better Attack Metastatic Melanoma, Penn Study Suggests
March 10, 2015
Treating metastatic melanoma with a tripple threat - including readiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways - could elicit an optimal response in more patients, ont that will boost the immune system's attack on the disease, suggests a new study from a multidisciplinary team of reearchers from Penn's Abramson Cancer Center published today in Nature. The study was led by authors Andy J. Minn, MD, PhD, assistant professor of Radiation Onclolgy, Robert Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research, Amit Maity, MD, PhD, professor of Radiation and Oncology, E. John Wherry, PhD, professor of Microbiology and director of the Insitute for Immunology at the Perelman School of Medicine at the University of Pennsylvania, and Lynn M. Schuchter, MD chief of Hematology/Oncology at Penn's Abramson Cancer Center.
March 5, 2015
In continuing coverage, a study showing that two of the four known groups of human AIDS viruses (HIV-1 groups O and P) originated in western lowland gorillas, appeared in several outlets. The international research team conducted a comprehensive survey of simian immunodeficiency viral infection in African gorillas. Coauthor Beatrice Hahn, MD, a professor of Medicine and Microbiology, was quoted.
March 3, 2015
Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to an international team of scientists. They conducted a comprehensive survey of simian immunodeficiency viral infection in African gorillas, published this week in the Proceedings of the National Academy of Science. Coauthor Beatrice Hahn, MD, a professor of Medicine and Microbiology, was quoted in several outlets, including the New York Times and the Los Angeles Times.
March 2, 2015
A VICE special report on efforts to treat cancer using the power of viruses and other immunotherapeutic approaches profiled Carl June, MD , a professor of Pathology and Laboratory Medicine and director of the Translational Research in the Abramson Cancer Center, and Stephan Grupp, MD, PhD, a professor of Pediatrics and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. Two pediatric patients who participated in the clinical trials of the Penn-developed cellular therapy known as CRL019 were also featured in the show.
February 20, 2015
Reporting in the Lancet Infectious Diseases, Shruthi Ravimohan, PhD, a research associate in the division of Infectious Diseases, and Gregory P. Bisson, MD, MSCE, an assistant professor in the division of Infectious Diseases and a senior scholar at the Center for Clinical Epidemiology and Biostatistics, evaluated over 200 patients in Botswana before and after they began antiretroviral therapy, and found several immune biomarkers that may help better stratify patients, and guide future research and treatments before HIV treatment begins.
February 17, 2015
Investigators with the National Institutes of Health have discovered the genomic switches of a blood cell key to regulating the human immune system. The findings, published in Nature today, open the door to new research and development in drugs and personalized medicine to help those with autoimmune disorders such as inflammatory bowel disease or rheumatoid arthritis. The lead author, Golnaz Vahedi, Ph.D., will be joining the Perelman School of Medicine in May 2015 as an Assistant Professor in the Department of Genetics.
February 16, 2015
A Fox News segment details progress in Penn's gene therapy trials for blood cancers, including the story of a patient who was one of the first participants in studies to test this new approach, who remains cancer-free more than four years later. One of the trial's leaders, David Porter, MD, a professor of Hematology-Oncology and director of Blood and Marrow Transplantation in the Abramson Cancer Center, is quoted in the story, and in a San Diego Union Tribune article recapping the results of the trials so far.
February 16, 2015
David Roth, MD, PhD, director of the Center for Personalized Diagnostics and chair of the department of Pathology and Laboratory Medicine, explained to the audience of SiriusXM's "POTUS" radio show that precision medicine helps diagnose individuals more accurately. Doctors are able to pinpoint a particular kind of illness a patient has and treat it more effectively, instead of a process of trial and error.
February 16, 2015
A Philadelphia Inquirer article asks: Can a modified vegan diet -- heavy of tofu, whole grains, fruits and vegetables, and low on saturated and trans fats -- significantly help with heart disease? Daniel Rader, MD director of the Preventative Cardiovascular Program, says that avoiding saturated and trans fats is the most important dietary change one can make to reduce the risk of heart disease.
February 10, 2015
A Prevention magazine article about improving your "heart age" includes advice from Daniel Rader, MD, director of the Preventative Cardiovascular Program. He says that for someone with a family history of heart disease, in addition to leading a healthy lifestyle, taking a statin can further reduce the risk of a heart attack.
February 9, 2015
A somatic gene mutation is a potential molecular marker for rare adrenal tumors, according to research by Katherine Nathanson and Lauren FIsbein of Medicine.
Inflammation Application: How Tumor-Causing Cells are Recruited in Cancers Linked to Chronic Inflammatory Diseases
February 9, 2015
Investigators including, Dmitry Gabrilovich, MD, PhD have demonstrated what is happening at a cellular level that allows for chronic inflammation to cause a variety of cancers; inflammatory conditions are associated with a specific phenotype of myeloid cells called immature granulocytic cells, they report.
February 9, 2015
Doctors treating patients battling both HIV and tuberculosis (TB) - many of whom live in Africa are faced with the decision when to start those patients on entrepreneurial therapy (ART) while they are being treated with antibiotics for active TB disease. Reporting in a new study published online this week in The Lancet Infectious Diseases, researchers under the Botswana-UPenn Partnership, including Shruthl Ravimohan, PhD, a research associate in the division of Infectious Disease, and Gregory P. Bisson, MD, MSCE an Assistant Professor in the division of Infectious Diseases, have identified immune biomarkers in these patients before they begin ART.
February 6, 2015
University of Pennsylvania and Imperial College London researchers learned in a new study that after ingesting a meal of blood, mosquitoes ramp up production of immune system proteins that help fight off the parasites that blood might contain. "This appears to be a new mechanism by which the mosquito is anticipating a parasite infection," said Michael Povelones, an assistant professor in Penn's School of Veterinary Medicine, who coauthored the study. A greater understanding of how mosquitoes naturally fight off infection could offer a strategy for preventing humans from getting infected with those same pathogens.
January 29, 2015
Slow-healing wounds are a serious problem for diabetics. A study led by Dental Medicine's Dana Graves has identified a molecule that may be responsible.
Penn Study Reveals Possible Therapeutic Target for Common, but Mysterious Brain Blood Vessel Disorder
January 27, 2015
Cardiovascular scientists at the Perelman School of Medicine at the University of Pennsylvania have studied a pathway in heart development to discover an important set of molecular signals, triggered by cerebral cavernous malformation-linked gene defects that potentially could be targeted to treat the disorder. “We hope that these findings will lead to a better understanding of the origins of CCM, and thus to treatment possibilities,” says Mark L. Kahn, MD, a professor of Cardiovascular Medicine, and senior author of the new study, published in Developmental Cell.
January 26, 2015
For his work in cancer biology, Xianxin Hua of Medicine has been awarded a Harrington Scholar-Innovator Award and $100,000 for two years to support his research.
January 23, 2015
Beatrice Hahn of Medicine will be honored by the American College of Physicians for her research on the origins of the human AIDS viruses and malaria parasites.
January 23, 2015
Based on a review led by Dental Medicine professor Thomas Sollecito, the ADA issued a new guideline regarding the use of antibiotics before dental procedures.
Mutated ATRX Gene Linked to Brain and Pancreatic Neuroendocrine Tumors is Potential Biomarker for Rare Adrenal Tumors Too
January 21, 2015
A somatic mutation in the ATRX gene recently demonstrating potential as a molecular marker for aggressive brain tumors could also serve as a biomarker for rare neuroendocrine tumors, according to a new Penn Medicine study in Nature Communications, reports Endocrine Today. “We have identified, for the first time, somatic ATRX mutations in pheochromocytomas and paragangliomas,” said Katherine Nathanson, MD, an associate professor in the division of Translational Medicine and Chief Oncogenomics Physician for the Abramson Cancer Center. The mutation could not only serve as that biomarker for metastatic disease, but also a potential therapeutic drug target in the future
December 22, 2014
A Philadelphia Business Journal blog post covered a newly-opened phase I clinical trial using hTERT DNA immunotherapy. The drug will be tested in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. The ultimate goal is to reduce the risk of relapse in these patients. "The next great wave of oncology advancements will be treatments which empower the patient's own immune system to seek and destroy cancer," said principal investigator, Robert Vonderheide, MD, PhD, the Hanna Wise Professor in Cancer Research in the Abramson Cancer Center.
December 17, 2014
A feature in The New Yorker on HIV/AIDS referenced a Penn Medicine study published in New England Journal of Medicine in March on HIV gene therapy and CCR5, a rare mutation that provides a natural resistance to the virus. In that study, Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of translational research at the Abramson Cancer Center, and colleagues successfully genetically engineered the immune cells of 12 HIV positive patients to resist infection, and decreased the viral loads of some patients taken off antiretroviral drug therapy entirely.
November 18, 2014
Lynn Wang from Carry the One Radio The Science Podcast in San Francisco spoke with Dr. John Wherry about evading the immune system. "Although our immune system s amazing at what it does, there are complex cases where it fails us. Everyday, our bodies fight off hordes of bacteria and viruses that cause disease. When fighting cancer, our bodies even face their own cells that have gone rogue. However, certain pathogens and cancers manage to circumvent our immune system."
November 13, 2014
News outlets across the U.S. and in the UK covered the story of an Abramson Cancer Center patient who participated in a Penn clinical trial in which his own immune cells were modified to target and attack his leukemia. Marshall Jensen, a 30-year-old musician, husband and father recently returned to his Utah hometown in remission after spending several months in Philadelphia receiving treatment. His cancer had come back several times previously despite chemotherapy drugs and bone marrow transplants. “’We were calling it our Hail Mary pass,’” he said of the Penn trial. 'It felt right. … We didn't know how we were going to get out there, what we were going to do, but it worked. By God's grace I was able to come back.” The Penn research team is led by Carl June, MD, and Jensen was treated by David Porter, MD, and Noelle Frey, MD.
November 7, 2014
"BBC Horizons" points to Dental Medicine's Henry Daniell and Physics' Charlie Johnson as innovators whose work may "change the world as we know it."
November 6, 2014
Ivanhoe reports on a clinical trial from Penn Medicine researchers who engineered the immune cells of 12 HIV positive patients to resist infection. The phase I study, led by Carl June, MD, professor of Pathology and Laboratory Medicine, Bruce L. Levine, PhD, associate professor of Pathology and Laboratory Medicine, and Pablo Tebas, MD, professor of Medicine in the division of Infectious Diseases, is the first successful clinical test of any gene editing approach in humans. CBS affiliates in Huntsville, AL., Anchorage and Juneau, Alaska, picked up the story. The clinical trial was also referenced in a MIT Technology article.
October 21, 2014
A new form of gene therapy for boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a life threatening condition also known as “bubble boy” disease, appears to be both safe and effective, according to a study by Frederic Bushman of the Perelman School of Medicine.
T Cell Therapy Puts Leukemia Patients in Extended Remission
October 16, 2014
Ninety percent of patients with acute lymphoblastic leukemia went into remission after participating in trials of a personalized cellular therapy, CTL019, in the Abramson Cancer Center and the Children’s Hospital of Philadelphia, according to new study published today by a Perelman School of Medicine research team in the New England Journal of Medicine. The team’s results, detailed in the New York Times, the Philadelphia Inquirer, Reuters, Bloomberg News, CBS3 and other news outlets, represent an unprecedented success in the fight against this type of cancer, in a group of patients whose diseases had defied conventional treatments. “With the initial patients, we didn't know if it was just lucky,” the study team’s leader, Carl H. June, MD a professor of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, told the New York Times. “It turns out it’s reproducible.”Stephan Grupp, MD, PhD, a professor of Pediatrics and director of Translational Research in the Center for Childhood Cancer Research at CHOP Noelle Frey, MD, MSCE, an assistant professor of Medicine in the Abramson Cancer Center, and David Porter, MD, a professor of Medicine and director of the Blood and Marrow Transplantation in the Abramson Cancer Center, are also quoted in news coverage of the new study.
Taubman Institute Awards Annual $100,000 Research Grant
October 13, 2014
The University of Michigan's A. Alfred Taubman Medical Research Institute presented its $100,000 Taubman Prize for Excellence in Translation Medical Science Friday to Carl June, MD, the Richard W. Vague Professor in Immunotherapy in Penn's department of Pathology and Laboratory Medicine. He was honored for his work developing a personalized cellular therapy for leukemia, in which a patient's own immune cells are engineered to fight their cancer.
October 10, 2014
George Shaw, MD, PhD, professor of Medicine and Microbiology, is featured in a video on Bill Gates' personal blog, "Gatesnotes." The post marks the 10th anniversary of Gates Foundation’s Grand Challenges in Global Health program and the general concept of catalytic philanthropy. Shaw's research on HIV is covered, which has received a Grand Challenge grant.
A Closer Look
September 19, 2014
A study led by Svetlana Fayngerts and Youhai Chen of Medicine shows that lipid chemical messengers may be effective in treating cancer and inflammatory disorders.
Exercise Boosts Tumor-fighting Ability of Chemotherapy, Penn Team Finds
September 18, 2014
Nursing's Joseph Libonati and Medicine’s Sandra Ryeom found that pairing exercise with chemotherapy made cancer drugs more effective at shrinking tumors in mice.
Perelman School of Medicine Cancer Research Shines on Stand Up To Cancer Telethon
September 8, 2014
Friday night's Stand Up To Cancer telethon - carried on a record 31 TV networks and live-streamed on Hulu and Yahoo - featured interviews with Perelman School of Medicine faculty members Carl June, MD, a professor of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, and Stephan Grupp, MD, PhD, a professor of Pediatrics and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia, discussing advances in personalized immunotherapy that have led to unprecedented outcomes for patients with leukemia. The SU2C-St. Baldrick's Pediatric Cancer Dream Team, which aims to expand this type of approach to other cancers, is co-led by Perelman School of Medicine faculty members at CHOP.
September 5, 2014
Using his plant-based drug delivery system, Henry Daniell of Dental Medicine led a study in mice that successfully prevented a common complication of hemophilia treatment.
July 24, 2014
Ronald Collman and Elizabeth Grice are among Medicine faculty integrating microbiomics into their work to see how bacteria, viruses and fungi help keep people healthy.
Progress on HIV/AIDS
July 18, 2014
Ian Frank, MD, professor in the division of Infectious Diseases and director of Anti-Retroviral Clinical Research in the Penn Center for AIDS Research, was a guest on WHYY's "Radio Times" with Marty Moss-Coane for a show on the progress of HIV/AIDS treatment and research. Where do we stand in the battle against the epidemic? Frank was joined by AIDS activists for a roundtable discussion—everything from the Mississippi baby to the recent loss of the AIDS researchers on the downed Malaysian flight was tackled. “This is a huge tragedy for everyone that lost their lives and for their families and friends,” said Frank. “This is a huge blow to the HIV community,” he added.
July 13, 2014
A war on pancreas cancer is underway right here at the Abramson Cancer Center. A story in Sunday’s Philadelphia Inquirer featured the work of Jeffrey Drebin, MD, chair of Surgery and the John Rhea Barton Professor of Surgery, and Robert Vonderheide, MD, the Hanna Wise Professor in Cancer Research in the ACC. Drebin and Vonderheide—both co-leads on Stand up to Cancer Dream Teams—are investigating new targeted therapies, immunotherapies, and more, to better the understand and treat the disease, which is projected to become this country's second-leading cancer killer. "We absolutely need to figure it out," said Vonderheide. "It's a medical emergency." Ongoing studies at the ACC have shed light on tumor biology and shown success with the antimalarial drug hydroxychloroquine. "We're not declaring victory,” Drebin told the Inquirer. “We're declaring progress.”.
July 9, 2014
In continuing coverage, WHYY radio talked to David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center, about the recent FDA "Breakthrough Therapy" designation awarded to Penn's immunotherapy to treat relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The designation--a first for a personalized cellular therapy to treat cancer-- should help expedite the review and approval process. "It allows us to work more collaboratively with the FDA so that the trials can be done efficiently so there can be proper and early oversight," Porter said. "Hopefully, it will be on a more rapid path to approval in the future."
July 7, 2014
The U.S. Food and Drug Administration awarded the University of Pennsylvania’s personalized immunotherapy—known as CTL019—its Breakthrough Therapy Designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL), reports the Wall Street Journal and Reuters. Such a designation expedites the development and review of new medicines that treat serious or life-threatening conditions. “Receiving the FDA’s Breakthrough Designation is an essential step in our work with Novartis to expand this therapy to patients across the world who desperately need new options to help them fight this disease,” said Carl June, MD, the Richard W. Vague Professor in Immunotherapy and director of Translational Research in the Abramson Cancer Center. CTL019 is the first personalized cellular therapy for the treatment of cancer to receive this important classification. The announcement was also covered by Agence France-Presse, the Philadelphia Business Journal, and Fierce Biotech.
Laser and Drones: June at Penn Medicine, in Photos
June 30, 2014
The University of Pennsylvania campus largely falls silent in the summer
months, but Penn Medicine keeps on truckin'. In fact, the month of June
featured two of my favorite photography assignments thus far: lasers
First up, we have E. John Wherry, PhD, director of the Institute for Immunology, and his Becton Dickenson LSR II flow cytometer. If you have no idea what that means, you're not alone — so Wherry was kind enough to explain it:
"This instrument allows us to assess up to 20 parameters simultaneously at a single cell level with an amazing rate of up to 20,000 cells/second," he wrote in an e-mail. "As a result we can perform detailed profiling of the function of immune cells in different disease states."
Long story short, it enables researchers to determine which therapies are working and why a given therapy is effective or ineffective. This ultimately helps us develop better therapies and determine which patients will respond to a given treatment.
On top of that, it looks really cool. Wherry popped the hood on it and let me take a few shots. You can see them — and Wherry — in the slideshow at the bottom of this post.
Penn Immunologist to Co-direct $12 Million Grant to Study Hepatitis
June 30, 2014
John Wherry, PhD, an associate professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and colleagues from Massachusetts General Hospital (MGH) are co-directing a $12 million grant to study immune responses in people who have been effectively cured of hepatitis C viral infection with new, high-potency antiviral drugs. This grant is part of the Cooperative Centers for Human Immunology program, administered by the National Institute of Allergy and Infectious Diseases.
June 19, 2014
IFI investigator, Daniel J. Powell Jr. Ph.D., has been selected by the
Board of Directors from the American Society of Gene & Cell Therapy
(ASGCT) for a 2014 Outstanding New Investigator Award. Dr. Powell was
selected from a competitive field of nominations based upon his
significant contributions to the field of gene and cell therapy. The
award ceremony and presentation session was held during the 17th Annual
Meeting in Washington DC on May 23 rd , 2014, and was attended by thousands of meeting participants. Below is a summary from his award presentation:
The Powell Lab is developing innovative immunotherapy strategies built upon clinical observations and studies in basic T cell biology. Adoptive T cell therapy using naturally-occurring tumor infiltrating lymphocytes (TILs) or peripheral blood T cells genetically modified to express a chimeric antigen receptor (CAR) can mediate comprehensive cancer elimination in patients, provided that highly avid, tumor antigen-specific T cells with the ability to proliferate and persist after infusion can be identified. We recently overcame one obstacle to widespread TIL therapy by showing that naturally-occurring tumor-reactive T cells in various cancers can be identified by their cell surface expression of the TNFR superfamily receptor, CD137, demonstrating a role for CD137 in the immunobiology of cancer. To instill T cells with enhanced ability to persist after infusion, we recently applied CAR technology as a tool to test the impact of various costimulatory signals on human CAR T cell survival following antigen encounter in vivo, and discovered a functional role for CD27 in human T cell memory formation. We also devised a novel dual CAR T cell approach where the TCR signal is dissociated from costimulatory signals in two independent CARs of distinct antigen specificity, thus delivering tumor-focused activity while comparatively sparing normal healthy tissues expressing a low level of single antigen. Lastly, to develop widespread T cell therapy, we pioneered a universal immune receptor approach that is adaptable in antigen specificity, allowing for highly personalized T cell generation based upon the repertoire of antigens expressed by each individual’s cancer cells. These strategies build on the early success of adoptive immunotherapy by addressing significant hurdles to otherwise safe and effective T cell therapy.